Genentech to file sc Actemra in US for RA in 2012
This article was originally published in Scrip
Executive Summary
Reporting positive results from a second trial investigating a subcutaneous (sc) formulation of its rheumatoid arthritis (RA) treatment, Actemra (tocilizumab; also known as RoActemra), Roche's Genentech unit said it intends to file for US approval of the product. The announcement is in line with the company's previously stated plans.